Conţinutul numărului revistei |
Articolul precedent |
Articolul urmator |
767 14 |
Ultima descărcare din IBN: 2023-09-20 15:17 |
Căutarea după subiecte similare conform CZU |
616.36-003.826:616.1 (2) |
Pathology of the digestive system. Complaints of the alimentary canal (1732) |
Pathology of the circulatory system, blood vessels. Cardiovascular complaints (975) |
SM ISO690:2012 FUIOR, Ana, FUIOR, Stela, PELTEC, Angela. Boala ficatului gras nonalcoolic: noi indici de risc de patologie cardiovasculară. In: Sănătate Publică, Economie şi Management în Medicină , 2017, nr. 4(74), pp. 107-113. ISSN 1729-8687. |
EXPORT metadate: Google Scholar Crossref CERIF DataCite Dublin Core |
Sănătate Publică, Economie şi Management în Medicină | ||||||
Numărul 4(74) / 2017 / ISSN 1729-8687 /ISSNe 2587-3873 | ||||||
|
||||||
CZU: 616.36-003.826:616.1 | ||||||
Pag. 107-113 | ||||||
|
||||||
Descarcă PDF | ||||||
Rezumat | ||||||
Non-alcoholic fatty liver disease (NAFLD) affects up to a third of the population worldwide and may confer increased cardiometabolic risk with consequent adverse cardiovascular outcomes independent of traditional cardiovascular risk factors and the metabolic syndrome. Cardiovascular diseases (CVD) are still the number one cause of death globally. NAFLD is a marker of pathological ectopic fat accumulation combined with a low-grade chronic inflammatory state. This disease leads to pathophysiological processes including abnormal glucose, fatty acid and lipoprotein metabolism, increased oxidative stress, deranged adipokine profile, hypercoagulability, endothelial dysfunction, and accelerated progression of atherosclerosis. Thus, atherosclerosis induces to a dysfunctional cardiometabolic phenotype with cardiovascular mortality representing the main mode of premature death in NAFLD. Novel biomarkers like gamma-glutamyltransferase, hemoglobin level, serum bilirubin and uric acid have been associated with risk of cardiovascular events in NAFLD. The understanding of relation between these markers, NAFLD and CVD could lead to better stratification of patients with high CV risk. |
||||||
Cuvinte-cheie non-alcoholic fatty liver disease, gamma-glutamyltransferase, uric acid, cardiovascular risks, hemoglobin level, serum bilirubin |
||||||
|